SLC transporters as therapeutic targets: emerging opportunities
The DOI matches its Crossref record; 213 of the 213 references it cites were found in a registry or an index.
Abstract
Solute carrier (SLC) transporters - a family of more than 300 membrane-bound proteins that facilitate the transport of a wide array of substrates across biological membranes - have important roles in physiological processes ranging from the cellular uptake of nutrients to the absorption of drugs and other xenobiotics. Several classes of marketed drugs target well-known SLC transporters, such as neurotransmitter transporters, and human genetic studies have provided powerful insight into the roles of more-recently characterized SLC transporters in both rare and common diseases, indicating a wealth of new therapeutic opportunities. This Review summarizes knowledge on the roles of SLC transporters in human disease, describes strategies to target such transporters, and highlights current and investigational drugs that modulate SLC transporters, as well as promising drug targets.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Representative ABC transporters are multi-drug resistance protein 1 (MDR1; P-gp; ABCB1), breast cancer resistance protein (BCRP; ABCG2) and multi-drug-resistance-associated protein 1 (MRP1, ABCC1), while solute carrier (SLC) transporters include organic anion transporters, organic cation transporters and organic anion transport polypeptides [115].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [115]
Citations
Cites
Zhang, J.-H., Chung, T. D. Y., & Oldenburg, K. R. (1999) · SLAS Discovery · doi:10.1177/108705719900400206 · Cited by 6,847 · cited 1×
“The concentration of the substrate probe and uptake time that produce the best Z’ assay sensitivity factor is selected; a Z’ > 0.8 is ideal for HTS, although Z’ > 0.5 is also acceptable 49 .”
InfluentialHost–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
The International IBD Genetics Consortium (IIBDGC), Jostins, L., Ripke, S., Weersma, R. K., Duerr, R. H., McGovern, D. P., Hui, K. Y., Lee, J. C., Philip Schumm, L., Sharma, Y., et al. (2012) · Nature · doi:10.1038/nature11582 · Cited by 4,722 · cited 1×
“…have been associated with human traits or disease include the following: SLC22A4 and SLC22A5, which are associated with inflammatory bowel disease 15–17 ; SLC2A9 , SLC22A11 and SLC22A12, which are associated with gout and uric acid levels 18–20 ; SLCO1B1 and SLCO1B3, which are associated with…”
Membrane transporters in drug development
The International Transporter Consortium, Giacomini, K. M., Huang, S.-M., Tweedie, D. J., Benet, L. Z., Brouwer, K. L. R., Chu, X., Dahlin, A., Evers, R., Fischer, V., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3028 · Cited by 3,340
Self-citationHopkins, A. L., & Groom, C. R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd892 · Cited by 3,305
A genome-wide association study identifies novel risk loci for type 2 diabetes
Sladek, R., Rocheleau, G., Rung, J., Dina, C., Shen, L., Serre, D., Boutin, P., Vincent, D., Belisle, A., Hadjadj, S., et al. (2007) · Nature · doi:10.1038/nature05616 · Cited by 2,993
A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants
Scott, L. J., Mohlke, K. L., Bonnycastle, L. L., Willer, C. J., Li, Y., Duren, W. L., Erdos, M. R., Stringham, H. M., Chines, P. S., Jackson, A. U., et al. (2007) · Science · doi:10.1126/science.1142382 · Cited by 2,753
Franke, A., McGovern, D. P. B., Barrett, J. C., Wang, K., Radford-Smith, G. L., Ahmad, T., Lees, C. W., Balschun, T., Lee, J., Roberts, R., et al. (2010) · Nature Genetics · doi:10.1038/ng.717 · Cited by 2,520
Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk
The International Consortium for Blood Pressure Genome-Wide Association Studies (2011) · Nature · doi:10.1038/nature10405 · Cited by 2,033
Exome sequencing identifies the cause of a mendelian disorder
Ng, S. B., Buckingham, K. J., Lee, C., Bigham, A. W., Tabor, H. K., Dent, K. M., Huff, C. D., Shannon, P. T., Jabs, E. W., Nickerson, D. A., et al. (2010) · Nature Genetics · doi:10.1038/ng.499 · Cited by 1,957
DrugBank 3.0: a comprehensive resource for 'Omics' research on drugs
Knox, C., Law, V., Jewison, T., Liu, P., Ly, S., Frolkis, A., Pon, A., Banco, K., Mak, C., Neveu, V., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq1126 · Cited by 1,831
Exome sequencing as a tool for Mendelian disease gene discovery
Bamshad, M. J., Ng, S. B., Bigham, A. W., Tabor, H. K., Emond, M. J., Nickerson, D. A., & Shendure, J. (2011) · Nature Reviews Genetics · doi:10.1038/nrg3031 · Cited by 1,673
The SLC2 (GLUT) family of membrane transporters
Mueckler, M., & Thorens, B. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.07.001 · Cited by 1,328
Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770
Van Goor, F., Hadida, S., Grootenhuis, P. D. J., Burton, B., Cao, D., Neuberger, T., Turnbull, A., Singh, A., Joubran, J., Hazlewood, A., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904709106 · Cited by 1,228
Simon, D. B., Nelson-Williams, C., Johnson Bia, M., Ellison, D., Karet, F. E., Morey Molina, A., Vaara, I., Iwata, F., Cushner, H. M., Koolen, M., et al. (1996) · Nature Genetics · doi:10.1038/ng0196-24 · Cited by 1,219
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ferrannini, E., Muscelli, E., Frascerra, S., Baldi, S., Mari, A., Heise, T., Broedl, U. C., & Woerle, H.-J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72227 · Cited by 1,134 · cited 1×
“Chronic dosing with empagliflozin for 4 weeks in these patients led to a significant decline in both glycated haemoglobin and fasting glucose levels 111 .”
Simon, D. B., Karet, F. E., Hamdan, J. M., Pietro, A. D., Sanjad, S. A., & Lifton, R. P. (1996) · Nature Genetics · doi:10.1038/ng0696-183 · Cited by 907
SLC6 Neurotransmitter Transporters: Structure, Function, and Regulation
Kristensen, A. S., Andersen, J., Jørgensen, T. N., Sørensen, L., Eriksen, J., Loland, C. J., Strømgaard, K., & Gether, U. (2011) · Pharmacological Reviews · doi:10.1124/pr.108.000869 · Cited by 864
Genome-wide association analyses identify 18 new loci associated with serum urate concentrations
Study, L. C., Köttgen, A., CARDIoGRAM Consortium, DIAGRAM Consortium, ICBP Consortium, MAGIC Consortium, Albrecht, E., Teumer, A., Vitart, V., Krumsiek, J., et al. (2013) · Nature Genetics · doi:10.1038/ng.2500 · Cited by 836
Cefalu, W. T., Leiter, L. A., Yoon, K.-H., Arias, P., Niskanen, L., Xie, J., Balis, D. A., Canovatchel, W., & Meininger, G. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60683-2 · Cited by 724
Nutrient transporters in cancer: Relevance to Warburg hypothesis and beyond
Ganapathy, V., Thangaraju, M., & Prasad, P. D. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.09.005 · Cited by 710
Gorboulev, V., Schürmann, A., Vallon, V., Kipp, H., Jaschke, A., Klessen, D., Friedrich, A., Scherneck, S., Rieg, T., Cunard, R., et al. (2012) · Diabetes · doi:10.2337/db11-1029 · Cited by 687
The SLC3 and SLC7 families of amino acid transporters
Fotiadis, D., Kanai, Y., & Palacín, M. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.10.007 · Cited by 680
Lin, C.-L. G., Bristol, L. A., Jin, L., Dykes-Hoberg, M., Crawford, T., Clawson, L., & Rothstein, J. D. (1998) · Neuron · doi:10.1016/s0896-6273(00)80997-6 · Cited by 671
The ABCs of membrane transporters in health and disease (SLC series): Introduction
Hediger, M. A., Clémençon, B., Burrier, R. E., & Bruford, E. A. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.12.009 · Cited by 646
Gout, P., Buckley, A., Simms, C., & Bruchovsky, N. (2001) · Leukemia · doi:10.1038/sj.leu.2402238 · Cited by 640 · cited 2×
“Sulfasalazine, which was initially developed as an anti-inflammatory drug to treat rheumatoid arthritis, was subsequently found to inhibit XCT 144 and has anticancer effects in various cancer xenograft models 143 .”
X-ray structure of dopamine transporter elucidates antidepressant mechanism
Penmatsa, A., Wang, K. H., & Gouaux, E. (2013) · Nature · doi:10.1038/nature12533 · Cited by 612
Timmerman, L. A., Holton, T., Yuneva, M., Louie, R. J., Padró, M., Daemen, A., Hu, M., Chan, D. A., Ethier, S. P., van ‘t Veer, L. J., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.08.020 · Cited by 573 · cited 3×
“…L-type amino acid transporter 1 (LAT1; also known as SLC7A5) 140,141 , ASC amino acid transporter 2 (ASCT2; also known as SLC1A5) 142 and cystine–glutamate exchange transporter (XCT; also known as SLC7A11) 143 ) are also overexpressed in a variety of tumours and may be potential anticancer targets.”
Targeting GLUT1 and the Warburg Effect in Renal Cell Carcinoma by Chemical Synthetic Lethality
Chan, D. A., Sutphin, P. D., Nguyen, P., Turcotte, S., Lai, E. W., Banh, A., Reynolds, G. E., Chi, J.-T., Wu, J., Solow-Cordero, D. E., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002394 · Cited by 557
Liu, Y., Cao, Y., Zhang, W., Bergmeier, S., Qian, Y., Akbar, H., Colvin, R., Ding, J., Tong, L., Wu, S., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0131 · Cited by 555
Paulusma, C. C., Kool, M., Bosma, P. J., Scheffer, G. L., ter Borg, F., Scheper, R. J., Tytgat, G. N., Borst, P., Baas, F., & Elferink, R. O. (1997) · Hepatology · doi:10.1002/hep.510250635 · Cited by 552
The SLC22 drug transporter family
Koepsell, H., & Endou, H. (2004) · Pfl�gers Archiv European Journal of Physiology · doi:10.1007/s00424-003-1089-9 · Cited by 525
Cha, S. H., Sekine, T., Fukushima, J.-I., Kanai, Y., Kobayashi, Y., Goya, T., & Endou, H. (2001) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12589-8 · Cited by 508
Loss-of-function mutations in SLC30A8 protect against type 2 diabetes
Go-T2D Consortium, Flannick, J., T2D-GENES Consortium, Thorleifsson, G., Beer, N. L., Jacobs, S. B. R., Grarup, N., Burtt, N. P., Mahajan, A., Fuchsberger, C., et al. (2014) · Nature Genetics · doi:10.1038/ng.2915 · Cited by 492
Wong, D. T., Horng, J. S., Bymaster, F. P., Hauser, K. L., & Molloy, B. B. (1974) · Life Sciences · doi:10.1016/0024-3205(74)90345-2 · Cited by 481
Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery
Zhu, F., Shi, Z., Qin, C., Tao, L., Liu, X., Xu, F., Zhang, L., Song, Y., Liu, X., Zhang, J., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr797 · Cited by 480
Apparent activity in high-throughput screening: origins of compound-dependent assay interference
Thorne, N., Auld, D. S., & Inglese, J. (2010) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2010.03.020 · Cited by 430
Furosemide effect on isolated perfused tubules
Burg, M., Stoner, L., Cardinal, J., & Green, N. (1973) · American Journal of Physiology-Legacy Content · doi:10.1152/ajplegacy.1973.225.1.119 · Cited by 430
Le Floch, R., Chiche, J., Marchiq, I., Naiken, T., Ilc, K., Murray, C. M., Critchlow, S. E., Roux, D., Simon, M.-P., & Pouysségur, J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1106123108 · Cited by 429
Study, L. C., Wain, L. V., EchoGen consortium, AortaGen Consortium, CHARGE Consortium Heart Failure Working Group, KidneyGen consortium, CKDGen consortium, Cardiogenics consortium, CardioGram, Verwoert, G. C., et al. (2011) · Nature Genetics · doi:10.1038/ng.922 · Cited by 428
Molecular cloning and functional expression of the bumetanide-sensitive Na-K-Cl cotransporter.
Xu, J. C., Lytle, C., Zhu, T. T., Payne, J. A., Benz, E., & Forbush, B. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.6.2201 · Cited by 424
Bile Acids and Metabolic Regulation
Staels, B., & Fonseca, V. A. (2009) · Diabetes Care · doi:10.2337/dc09-s355 · Cited by 415
Antidepressant binding site in a bacterial homologue of neurotransmitter transporters
Singh, S. K., Yamashita, A., & Gouaux, E. (2007) · Nature · doi:10.1038/nature06038 · Cited by 413
Chen, J. J., Li, Z., Pan, H., Murphy, D. L., Tamir, H., Koepsell, H., & Gershon, M. D. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-16-06348.2001 · Cited by 397
Update on gout: new therapeutic strategies and options
Terkeltaub, R. (2010) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2009.236 · Cited by 387
The SLCO (former SLC21) superfamily of transporters
Hagenbuch, B., & Stieger, B. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.10.009 · Cited by 385
Oelkers, P., Kirby, L. C., Heubi, J. E., & Dawson, P. A. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119355 · Cited by 385
van de Steeg, E., Stránecký, V., Hartmannová, H., Nosková, L., Hřebíček, M., Wagenaar, E., van Esch, A., de Waart, D. R., Oude Elferink, R. P. J., Kenworthy, K. E., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59526 · Cited by 384
Islet β-cell secretion determines glucagon release from neighbouring α-cells
Ishihara, H., Maechler, P., Gjinovci, A., Herrera, P.-L., & Wollheim, C. B. (2003) · Nature Cell Biology · doi:10.1038/ncb951 · Cited by 383
Activity of the Monocarboxylate Transporter 1 Inhibitor AZD3965 in Small Cell Lung Cancer
Polański, R., Hodgkinson, C. L., Fusi, A., Nonaka, D., Priest, L., Kelly, P., Trapani, F., Bishop, P. W., White, A., Critchlow, S. E., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2270 · Cited by 378
Nicolson, T. J., Bellomo, E. A., Wijesekara, N., Loder, M. K., Baldwin, J. M., Gyulkhandanyan, A. V., Koshkin, V., Tarasov, A. I., Carzaniga, R., Kronenberger, K., et al. (2009) · Diabetes · doi:10.2337/db09-0551 · Cited by 375
Wong, D. T., Bymaster, F. P., Horng, J. S., & Molloy, B. B. (1975) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)30202-8 · Cited by 373
A High-Throughput Screen for Aggregation-Based Inhibition in a Large Compound Library
Feng, B. Y., Simeonov, A., Jadhav, A., Babaoglu, K., Inglese, J., Shoichet, B. K., & Austin, C. P. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm061317y · Cited by 358
SLC1A5 Mediates Glutamine Transport Required for Lung Cancer Cell Growth and Survival
Hassanein, M., Hoeksema, M. D., Shiota, M., Qian, J., Harris, B. K., Chen, H., Clark, J. E., Alborn, W. E., Eisenberg, R., & Massion, P. P. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2334 · Cited by 351
Airley, R. E., & Mobasheri, A. (2007) · Chemotherapy · doi:10.1159/000104457 · Cited by 342
LeuT-Desipramine Structure Reveals How Antidepressants Block Neurotransmitter Reuptake
Zhou, Z., Zhen, J., Karpowich, N. K., Goetz, R. M., Law, C. J., Reith, M. E. A., & Wang, D.-N. (2007) · Science · doi:10.1126/science.1147614 · Cited by 333
Lehenkari, P. P., Kellinsalmi, M., Näpänkangas, J. P., Ylitalo, K. V., Mönkkönen, J., Rogers, M. J., Azhayev, A., Väänänen, H. K., & Hassinen, I. E. (2002) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)12222-5 · Cited by 333
The SLC1 high-affinity glutamate and neutral amino acid transporter family
Kanai, Y., Clémençon, B., Simonin, A., Leuenberger, M., Lochner, M., Weisstanner, M., & Hediger, M. A. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2013.01.001 · Cited by 329
A Genomewide Association Study of Skin Pigmentation in a South Asian Population
Stokowski, R. P., Pant, P. V. K., Dadd, T., Fereday, A., Hinds, D. A., Jarman, C., Filsell, W., Ginger, R. S., Green, M. R., van der Ouderaa, F. J., et al. (2007) · The American Journal of Human Genetics · doi:10.1086/522235 · Cited by 315
Chemical predictive modelling to improve compound quality
Cumming, J. G., Davis, A. M., Muresan, S., Haeberlein, M., & Chen, H. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4128 · Cited by 311
The GLUT9 Gene Is Associated with Serum Uric Acid Levels in Sardinia and Chianti Cohorts
Li, S., Sanna, S., Maschio, A., Busonero, F., Usala, G., Mulas, A., Lai, S., Dei, M., Orrù, M., Albai, G., et al. (2007) · PLoS Genetics · doi:10.1371/journal.pgen.0030194 · Cited by 310
Glucose transport families SLC5 and SLC50
Wright, E. M. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.11.002 · Cited by 301
Guo, H. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg267 · Cited by 284
Rask-Andersen, M., Masuram, S., & Schiöth, H. B. (2014) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-135943 · Cited by 282
Tumor Metabolism of Lactate: The Influence and Therapeutic Potential for MCT and CD147 Regulation
Kennedy, K. M., & Dewhirst, M. W. (2010) · Future Oncology · doi:10.2217/fon.09.145 · Cited by 280
Katsuno, K., Fujimori, Y., Takemura, Y., Hiratochi, M., Itoh, F., Komatsu, Y., Fujikura, H., & Isaji, M. (2007) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.110296 · Cited by 267
Riluzole, Neuroprotection and Amyotrophic Lateral Sclerosis
Cheah, B. C., Vucic, S., Krishnan, A., & Kiernan, M. C. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710791163939 · Cited by 258
Forst, T., Guthrie, R., Goldenberg, R., Yee, J., Vijapurkar, U., Meininger, G., & Stein, P. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12273 · Cited by 255
Monocarboxylate transporters (MCTs) in gliomas: expression and exploitation as therapeutic targets
Miranda-Gonçalves, V., Honavar, M., Pinheiro, C., Martinho, O., Pires, M. M., Pinheiro, C., Cordeiro, M., Bebiano, G., Costa, P., Palmeirim, I., et al. (2013) · Neuro-Oncology · doi:10.1093/neuonc/nos298 · Cited by 252
Monocarboxylate transporter MCT1 is a target for immunosuppression
Murray, C. M., Hutchinson, R., Bantick, J. R., Belfield, G. P., Benjamin, A. D., Brazma, D., Bundick, R. V., Cook, I. D., Craggs, R. I., Edwards, S., et al. (2005) · Nature Chemical Biology · doi:10.1038/nchembio744 · Cited by 248
Riluzole enhances the activity of glutamate transporters GLAST, GLT1 and EAAC1
Fumagalli, E., Funicello, M., Rauen, T., Gobbi, M., & Mennini, T. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2007.10.023 · Cited by 246
Zambrowicz, B., Freiman, J., Brown, P. M., Frazier, K. S., Turnage, A., Bronner, J., Ruff, D., Shadoan, M., Banks, P., Mseeh, F., et al. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2012.58 · Cited by 243
The diabetes-susceptible gene SLC30A8/ZnT8 regulates hepatic insulin clearance
Tamaki, M., Fujitani, Y., Hara, A., Uchida, T., Tamura, Y., Takeno, K., Kawaguchi, M., Watanabe, T., Ogihara, T., Fukunaka, A., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68807 · Cited by 238
Jadhav, A., Ferreira, R. S., Klumpp, C., Mott, B. T., Austin, C. P., Inglese, J., Thomas, C. J., Maloney, D. J., Shoichet, B. K., & Simeonov, A. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm901070c · Cited by 238
Genome-wide association meta-analysis for total serum bilirubin levels
Johnson, A. D., Kavousi, M., Smith, A. V., Chen, M.-H., Dehghan, A., Aspelund, T., Lin, J.-P., van Duijn, C. M., Harris, T. B., Cupples, L. A., et al. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp202 · Cited by 238
A Furosemide-Sensitive Cotransport of Sodium plus Potassium in the Human Red Cell
Wiley, J. S., & Cooper, R. A. (1974) · Journal of Clinical Investigation · doi:10.1172/jci107613 · Cited by 237
Novel Breast Cancer Susceptibility Locus at 9q31.2: Results of a Genome-Wide Association Study
Fletcher, O., Johnson, N., Orr, N., Hosking, F. J., Gibson, L. J., Walker, K., Zelenika, D., Gut, I., Heath, S., Palles, C., et al. (2011) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djq563 · Cited by 236
L‐type amino acid transporter 1 as a potential molecular target in human astrocytic tumors
Nawashiro, H., Otani, N., Shinomiya, N., Fukui, S., Ooigawa, H., Shima, K., Matsuo, H., Kanai, Y., & Endou, H. (2006) · International Journal of Cancer · doi:10.1002/ijc.21866 · Cited by 236
Role of the Intestinal Bile Acid Transporters in Bile Acid and Drug Disposition
Dawson, P. A. (2011) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-14541-4_4 · Cited by 227
Fujimori, Y., Katsuno, K., Nakashima, I., Ishikawa-Takemura, Y., Fujikura, H., & Isaji, M. (2008) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.140210 · Cited by 221
Blood pressure effects of sodium–glucose co-transport 2 (SGLT2) inhibitors
Oliva, R. V., & Bakris, G. L. (2014) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2014.02.003 · Cited by 219
Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain
Harvey, R. J., & Yee, B. K. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3893 · Cited by 214
Structure-based ligand discovery for the Large-neutral Amino Acid Transporter 1, LAT-1
Geier, E. G., Schlessinger, A., Fan, H., Gable, J. E., Irwin, J. J., Sali, A., & Giacomini, K. M. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1218165110 · Cited by 212
Self-citationSu, Z.-Z., Leszczyniecka, M., Kang, D.-C., Sarkar, D., Chao, W., Volsky, D. J., & Fisher, P. B. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0136555100 · Cited by 199
Monocarboxylate transporter 1 is up‐regulated in basal‐like breast carcinoma
Pinheiro, C., Albergaria, A., Paredes, J., Sousa, B., Dufloth, R., Vieira, D., Schmitt, F., & Baltazar, F. (2010) · Histopathology · doi:10.1111/j.1365-2559.2010.03560.x · Cited by 189
The solute carrier family 10 (SLC10): Beyond bile acid transport
Claro da Silva, T., Polli, J. E., & Swaan, P. W. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.07.004 · Cited by 181
Apical Sodium Dependent Bile Acid Transporter (ASBT, SLC10A2): A Potential Prodrug Target
Balakrishnan, A., & Polli, J. E. (2006) · Molecular Pharmaceutics · doi:10.1021/mp060022d · Cited by 178
Haase, J., & Brown, E. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.10.002 · Cited by 175
Ohtake, Y., Sato, T., Kobayashi, T., Nishimoto, M., Taka, N., Takano, K., Yamamoto, K., Ohmori, M., Yamaguchi, M., Takami, K., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300884k · Cited by 174
Mutations in a Thiamine-Transporter Gene and Wernicke's-like Encephalopathy
Kono, S., Miyajima, H., Yoshida, K., Togawa, A., Shirakawa, K., & Suzuki, H. (2009) · New England Journal of Medicine · doi:10.1056/nejmc0809100 · Cited by 170
Kido, Y., Matsson, P., & Giacomini, K. M. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2001629 · Cited by 169
Self-citationJutabha, P., Anzai, N., Kitamura, K., Taniguchi, A., Kaneko, S., Yan, K., Yamada, H., Shimada, H., Kimura, T., Katada, T., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.121301 · Cited by 159
Lindhurst, M. J., Fiermonte, G., Song, S., Struys, E., De Leonardis, F., Schwartzberg, P. L., Chen, A., Castegna, A., Verhoeven, N., Mathews, C. K., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607661103 · Cited by 158
Small-molecule activator of glutamate transporter EAAT2 translation provides neuroprotection
Kong, Q., Chang, L.-C., Takahashi, K., Liu, Q., Schulte, D. A., Lai, L., Ibabao, B., Lin, Y., Stouffer, N., Mukhopadhyay, C. D., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci66163 · Cited by 156
A Genome-Wide Scan of Ashkenazi Jewish Crohn's Disease Suggests Novel Susceptibility Loci
Kenny, E. E., Pe'er, I., Karban, A., Ozelius, L., Mitchell, A. A., Ng, S. M., Erazo, M., Ostrer, H., Abraham, C., Abreu, M. T., et al. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002559 · Cited by 153
Rafnar, Þ., Vermeulen, S. H. H. M., Sulem, P., Þorleifsson, G., Aben, K. K. H., Witjes, J. A., Grotenhuis, A. J., Verhaegh, G. W. C. T., de Kaa, C. A. H., Besenbacher, S., et al. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr303 · Cited by 153
Mutant deoxynucleotide carrier is associated with congenital microcephaly
Rosenberg, M. J., Agarwala, R., Bouffard, G. G., Davis, J., Fiermonte, G., Hilliard, M. S., Koch, T., Kalikin, L. M., Makałowska, I., Morton, D. H., et al. (2002) · Nature Genetics · doi:10.1038/ng948 · Cited by 152
Pedersen, J. M., Matsson, P., Bergström, C. A. S., Hoogstraate, J., Norén, A., LeCluyse, E. L., & Artursson, P. (2013) · Toxicological Sciences · doi:10.1093/toxsci/kft197 · Cited by 148
Glutamate Transporter EAAT2: A New Target For The Treatment Of Neurodegenerative Diseases
Lin, C.-L. G., Kong, Q., Cuny, G. D., & Glicksman, M. A. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.122 · Cited by 146
Physiology and pathophysiology of SLC12A1/2 transporters
Markadieu, N., & Delpire, E. J. (2013) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-013-1370-5 · Cited by 145
Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders
Jankovic, J., & Clarence-Smith, K. (2011) · Expert Review of Neurotherapeutics · doi:10.1586/ern.11.149 · Cited by 145
Wittwer, M. B., Zur, A. A., Khuri, N., Kido, Y., Kosaka, A., Zhang, X., Morrissey, K. M., Sali, A., Huang, Y., & Giacomini, K. M. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301302s · Cited by 142
Self-citationGenome-Wide Association Study of Tanning Phenotype in a Population of European Ancestry
Nan, H., Kraft, P., Qureshi, A. A., Guo, Q., Chen, C., Hankinson, S. E., Hu, F. B., Thomas, G., Hoover, R. N., Chanock, S., et al. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.62 · Cited by 138
Impact of genetic variation in OATP transporters to drug disposition and response
Gong, I. Y., & Kim, R. B. (2013) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.dmpk-12-rv-099 · Cited by 137
Self-citationSpinal Antiallodynia Action of Glycine Transporter Inhibitors in Neuropathic Pain Models in Mice
Morita, K., Motoyama, N., Kitayama, T., Morioka, N., Kifune, K., & Dohi, T. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.136267 · Cited by 135
Guan, J., Lo, M., Dockery, P., Mahon, S., Karp, C. M., Buckley, A. R., Lam, S., Gout, P. W., & Wang, Y.-Z. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0894-4 · Cited by 134
Pedersen, J. M., Matsson, P., Bergström, C. A. S., Norinder, U., Hoogstraate, J. A., & Artursson, P. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7015683 · Cited by 131
Sanna, S., Busonero, F., Maschio, A., McArdle, P. F., Usala, G., Dei, M., Lai, S., Mulas, A., Piras, M. G., Perseu, L., et al. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp203 · Cited by 129
Schlessinger, A., Geier, E., Fan, H., Irwin, J. J., Shoichet, B. K., Giacomini, K. M., & Sali, A. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1106030108 · Cited by 128
Self-citationInhibition of L-type amino acid transporter 1 has antitumor activity in non-small cell lung cancer.
Imai, H., Kaira, K., Oriuchi, N., Shimizu, K., Tominaga, H., Yanagitani, N., Sunaga, N., Ishizuka, T., Nagamori, S., Promchan, K., et al. (2010) · PubMed · Cited by 127
Tin, A., Woodward, O. M., Kao, W. H. L., Liu, C.-T., Lu, X., Nalls, M. A., Shriner, D., Semmo, M., Akylbekova, E. L., Wyatt, S. B., et al. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr307 · Cited by 127
Jeon, B. S., Kim, J. M., Jeong, J. M., Kim, K., Chang, Y., Lee, D. S., & Lee, M. C. (1998) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.65.1.60 · Cited by 125
Na+-H+ Exchanger, pH Regulation and Cancer
J. Reshkin, S., A. Cardone, R., & Harguindey, S. (2012) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/15748928130108 · Cited by 125
Crystal structure of a concentrative nucleoside transporter from Vibrio cholerae at 2.4 Å
Johnson, Z. L., Cheong, C.-G., & Lee, S.-Y. (2012) · Nature · doi:10.1038/nature10882 · Cited by 120
Zhang, Q., Zhang, Y., Diamond, S., Boer, J., Harris, J. J., Li, Y., Rupar, M. J., Behshad, E., Gardiner, C. M., Collier, P., et al. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.058883 · Cited by 119
A high prevalence of renal hypouricemia caused by inactive SLC22A12 in Japanese
Iwai, N., Mino, Y., Hosoyamada, M., Tago, N., Kokubo, Y., & Endou, H. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00839.x · Cited by 118
A role for the organic anion transporter OAT3 in renal creatinine secretion in mice
Vallon, V., Eraly, S. A., Rao, S. R., Gerasimova, M., Rose, M., Nagle, M., Anzai, N., Smith, T., Sharma, K., Nigam, S. K., et al. (2012) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00013.2012 · Cited by 116
Riluzole elevates GLT-1 activity and levels in striatal astrocytes
Carbone, M., Duty, S., & Rattray, M. (2012) · Neurochemistry International · doi:10.1016/j.neuint.2011.10.017 · Cited by 114
Jeon, B. S., Jeong, J., Park, S. S., Kim, J., Chang, Y., Song, H., Kim, K., Yoon, K., Lee, M. C., & Lee, S. (1998) · Annals of Neurology · doi:10.1002/ana.410430614 · Cited by 114
Comparison of human solute carriers
Schlessinger, A., Matsson, P., Shima, J. E., Pieper, U., Yee, S. W., Kelly, L., Apeltsin, L., Stroud, R. M., Ferrin, T. E., Giacomini, K. M., et al. (2010) · Protein Science · doi:10.1002/pro.320 · Cited by 114
Self-citationBiotin-Responsive Basal Ganglia Disease in Ethnic Europeans With Novel SLC19A3 Mutations
Debs, R., Depienne, C., Rastetter, A., Bellanger, A., Degos, B., Damien Galanaud, E., Keren, B., Lyon‐Caen, O., Brice, A., & Sedel, F. (2010) · Archives of Neurology · doi:10.1001/archneurol.2009.293 · Cited by 113
Nutrient transporters: the Achilles’ heel of anabolism
McCracken, A. N., & Edinger, A. L. (2013) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2013.01.002 · Cited by 113
Solute carriers as drug targets: Current use, clinical trials and prospective
Rask‐Andersen, M., Masuram, S., Fredriksson, R., & Schiöth, H. B. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.07.015 · Cited by 110
Jauregui-Osoro, M., Sunassee, K., Weeks, A. J., Berry, D. J., Paul, R. L., Cleij, M. C., Banga, J. P., O'Doherty, M. J., Marsden, P. K., Clarke, S. E., et al. (2010) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-010-1523-0 · Cited by 108
Apical Transporters for Neutral Amino Acids: Physiology and Pathophysiology
Bröer, S. (2008) · Physiology · doi:10.1152/physiol.00045.2007 · Cited by 107
Gui, C., Obaidat, A., Chaguturu, R., & Hagenbuch, B. (2010) · Current Chemical Genomics · doi:10.2174/1875397301004010001 · Cited by 107
Schmitt, A., Mössner, R., Gossmann, A., Fischer, I. G., Gorboulev, V., Murphy, D. L., Koepsell, H., & Lesch, K. P. (2003) · Journal of Neuroscience Research · doi:10.1002/jnr.10521 · Cited by 102
Kelley, R. I., Robinson, D., Puffenberger, E. G., Strauss, K. A., & Morton, D. H. (2002) · American Journal of Medical Genetics · doi:10.1002/ajmg.10529 · Cited by 100
Izumi, S., Nozaki, Y., Komori, T., Maeda, K., Takenaka, O., Kusano, K., Yoshimura, T., Kusuhara, H., & Sugiyama, Y. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.052290 · Cited by 99
Zinc as a paracrine effector in pancreatic islet cell death.
Kim, B. J., Kim, Y. H., Kim, S., Kim, J. W., Koh, J. Y., Oh, S. H., Lee, M. K., Kim, K. W., & Lee, M. S. (2000) · Diabetes · doi:10.2337/diabetes.49.3.367 · Cited by 99
Glycine transport inhibitors for the treatment of pain
Vandenberg, R. J., Ryan, R. M., Carland, J. E., Imlach, W. L., & Christie, M. J. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.05.006 · Cited by 99
Cyclocreatine treatment improves cognition in mice with creatine transporter deficiency
Kurosawa, Y., DeGrauw, T. J., Lindquist, D. M., Blanco, V. M., Pyne-Geithman, G. J., Daikoku, T., Chambers, J. B., Benoit, S. C., & Clark, J. F. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59373 · Cited by 98
Molecular Modeling and Ligand Docking for Solute Carrier (SLC) Transporters
Schlessinger, A., Khuri, N., Giacomini, K. M., & Šali, A. (2013) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026611313070007 · Cited by 94
Self-citationCanagliflozin: A Review of Its Use in Patients with Type 2 Diabetes Mellitus
Plosker, G. L. (2014) · Drugs · doi:10.1007/s40265-014-0225-5 · Cited by 93
Computational Models for Drug Inhibition of the Human Apical Sodium-Dependent Bile Acid Transporter
Zheng, X., Ekins, S., Raufman, J.-P., & Polli, J. E. (2009) · Molecular Pharmaceutics · doi:10.1021/mp900163d · Cited by 93
Solute carriers (SLCs) in cancer
El-Gebali, S., Bentz, S., Hediger, M. A., & Anderle, P. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2012.12.007 · Cited by 92
Yang, Z., Philips, J. D., Doty, R. T., Giraudi, P., Ostrow, J. D., Tiribelli, C., Smith, A., & Abkowitz, J. L. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.119131 · Cited by 89
Schlessinger, A., Yee, S. W., Sali, A., & Giacomini, K. M. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.73 · Cited by 86
Self-citationLee, Y., Jun, H. S., Pan, C., Lin, S. R., Wilson, L. H., Mansfield, B. C., & CHOU, J. Y. (2012) · Hepatology · doi:10.1002/hep.25717 · Cited by 86
Impact on Bone of an Estrogen Receptor-α Gene Loss of Function Mutation
Smith, E. P., Specker, B., Bachrach, B. E., Kimbro, K. S., Li, X. J., Young, M. F., Fedarko, N. S., Abuzzahab, M. J., Frank, G. R., Cohen, R. M., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2397 · Cited by 84
Shibazaki, T., Tomae, M., Ishikawa-Takemura, Y., Fushimi, N., Itoh, F., Yamada, M., & Isaji, M. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.193045 · Cited by 84
Colton, C. K., Kong, Q., Lai, L., Zhu, M. X., Seyb, K. I., Cuny, G. D., Xian, J., Glicksman, M. A., & Glenn Lin, C.-L. (2010) · SLAS Discovery · doi:10.1177/1087057110370998 · Cited by 83
Hunting human disease genes: lessons from the past, challenges for the future
Brunham, L. R., & Hayden, M. R. (2013) · Human Genetics · doi:10.1007/s00439-013-1286-3 · Cited by 82
Hoffman, L. R., & Ramsey, B. W. (2013) · CHEST Journal · doi:10.1378/chest.12-1639 · Cited by 82
Treatment of intractable epilepsy in a female with SLC6A8 deficiency
Mercimek‐Andrews, S., Connolly, M. B., Poskitt, K. J., Horvath, G. A., Lowry, N. J., Salomons, G. S., Casey, B. M., Sinclair, G. B., Davis, C., Jakobs, C., et al. (2010) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2010.08.016 · Cited by 80
NHE-1: A Promising Target for Novel Anti-cancer Therapeutics
Loo, S. Y., Chang, M. K. X., Chua, C. S. H., Kumar, A. P., Pervaiz, S., & Clement, M. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212799504885 · Cited by 80
Wu, Y., Aquino, C. J., Cowan, D. J., Anderson, D. L., Ambroso, J. L., Bishop, M. J., Boros, E. E., Chen, L., Cunningham, A., Dobbins, R. L., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400459m · Cited by 79
Carrigan, C. N., Bartlett, R. D., Esslinger, C. S., Cybulski, K. A., Tongcharoensirikul, P., Bridges, R. J., & Thompson, C. M. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm010261z · Cited by 75
Pharmacophore Modelling: A Forty Year Old Approach and its Modern Synergies
Caporuscio, F., & Tafi, A. (2011) · Current Medicinal Chemistry · doi:10.2174/092986711795933669 · Cited by 75
Hu, G., Henke, A., Karpowicz, R. J., Sonders, M. S., Farrimond, F., Edwards, R. H., Sulzer, D., & Sameš, D. (2013) · ACS Chemical Biology · doi:10.1021/cb400259n · Cited by 74
Aberrant Detergent-Insoluble Excitatory Amino Acid Transporter 2 Accumulates in Alzheimer Disease
Woltjer, R. L., Duerson, K., Fullmer, J. M., Mookherjee, P., Ryan, A. M., Montine, T. J., Kaye, J. A., Quinn, J. F., Silbert, L., Erten-Lyons, D., et al. (2010) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181e24adb · Cited by 72
Impaired Intestinal Vitamin B1 (Thiamin) Uptake in Thiamin Transporter-2–Deficient Mice
Reidling, J. C., Lambrecht, N., Kassir, M., & Said, H. M. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.10.042 · Cited by 71
Fujimori, Y., Katsuno, K., Ojima, K., Nakashima, I., Nakano, S., Ishikawa-Takemura, Y., Kusama, H., & Isaji, M. (2009) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.03.007 · Cited by 71
Bielinski, S. J., Chai, H. S., Pathak, J., Talwalkar, J. A., Limburg, P. J., Gullerud, R. E., Sicotte, H., Klee, E. W., Ross, J., Kocher, J.-P. A., et al. (2011) · Mayo Clinic Proceedings · doi:10.4065/mcp.2011.0178 · Cited by 70
Esslinger, C. S., Agarwal, S. R., Gerdes, J. M., Wilson, P. A., Davis, E. S., Awes, A. N., O’Brien, E. M., Mavencamp, T., Koch, H. P., Poulsen, D. J., et al. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.08.009 · Cited by 68
The Vesicular Monoamine Transporter-2
Nickell, J. R., Siripurapu, K. B., Vartak, A., Crooks, P. A., & Dwoskin, L. P. (2014) · Advances in Pharmacology · doi:10.1016/b978-0-12-420118-7.00002-0 · Cited by 66
Abrahamsen, B., Schneider, N., Erichsen, M. N., Huynh, T. H. V., Fahlke, C. M., Bunch, L., & Jensen, A. A. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.3396-12.2013 · Cited by 65
Increased vesicular glutamate transporter expression causes excitotoxic neurodegeneration
Daniels, R. W., Miller, B. R., & DiAntonio, A. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.10.009 · Cited by 64
Inhibitors of the Glutamate Vesicular Transporter (VGLUT)
Thompson, C., Davis, E., Carrigan, C., Cox, H., Bridges, R., & Gerdes, J. (2005) · Current Medicinal Chemistry · doi:10.2174/0929867054637635 · Cited by 64
Lin, S.-C., Lin, K., Hsiao, I., Hsieh, C., Lin, W., Lu, C., Wey, S., Yen, T., Kung, M., & Weng, Y.-H. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.121897 · Cited by 62
Johnson, Z. L., Lee, J.-H., Lee, K., et al. (2014) · eLife · doi:10.7554/elife.03604 · Cited by 60
Crittenden, D. B., & Pillinger, M. H. (2013) · Annual Review of Medicine · doi:10.1146/annurev-med-080911-105830 · Cited by 59
Genetic Implication of a Novel Thiamine Transporter in Human Hypertension
Zhang, K., Huentelman, M. J., Rao, F., Sun, E. I., Corneveaux, J. J., Schork, A. J., Wei, Z., Waalen, J., Miramontes-Gonzalez, J. P., Hightower, C. M., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.01.007 · Cited by 53
Glycogen Storage Disease Type I
Bali, D. S., Chen, Y.-T., Austin, S. L., & Goldstein, J. (2016) · Europe PMC (PubMed Central) · Cited by 51
Schlessinger, A., Wittwer, M., Dahlin, A., Khuri, N., Bonomi, M., Fan, H., Giacomini, K. M., & Šali, A. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.388157 · Cited by 50
Self-citationPET Radioligands for the Vesicular Acetylcholine Transporter (VAChT)
Giboureau, N., Som, I. M., Boucher-Arnold, A., Guilloteau, D., & Kassiou, M. (2010) · Current Topics in Medicinal Chemistry · doi:10.2174/156802610793176846 · Cited by 49
Urate Transporters: An Evolving Field
Anzai, N., & Endou, H. (2011) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2011.08.003 · Cited by 48
Sodani, K., Patel, A., Anreddy, N., Singh, S., Yang, D.-H., Kathawala, R. J., Kumar, P., Talele, T. T., & Chen, Z.-S. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.02.012 · Cited by 47
Nogami, T., Takano, H., Arakawa, R., Ichimiya, T., Fujiwara, H., Kimura, Y., Kodaka, F., Sasaki, T., Takahata, K., Suzuki, M., et al. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712001009 · Cited by 46
Yiu, W. H., Pan, C. J., Allamarvdasht, M., Kim, S. Y., & CHOU, J. Y. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302869 · Cited by 45
Luethi, E., Nguyen, K. T., Bürzle, M., Blum, L. C., Suzuki, Y., Hediger, M., & Reymond, J.-L. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100959g · Cited by 45
Weeks, A. J., Jauregui-Osoro, M., Cleij, M. C., Blower, J. E., Ballinger, J. R., & Blower, P. J. (2010) · Nuclear Medicine Communications · doi:10.1097/mnm.0b013e3283419540 · Cited by 44
A Pairwise Chemical Genetic Screen Identifies New Inhibitors of Glucose Transport
Ulanovskaya, O. A., Cui, J., Kron, S. J., & Kozmin, S. A. (2011) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.12.015 · Cited by 43
Genetics of Hyperuricemia and Gout: Implications for the Present and Future
George, R. L., & Keenan, R. T. (2013) · Current Rheumatology Reports · doi:10.1007/s11926-012-0309-8 · Cited by 43
Glutamate Transporters as Drug Targets
Hinoi, E., Takarada, T., Tsuchihashi, Y., & Yoneda, Y. (2005) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1568007053544093 · Cited by 42
Statins, fibrates and retinoic acid upregulate mitochondrial acylcarnitine carrier gene expression
Iacobazzi, V., Convertini, P., Infantino, V., Scarcia, P., Todisco, S., & Palmieri, F. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.08.008 · Cited by 40
Hume, W. E., Shingaki, T., Takashima, T., Hashizume, Y., Okauchi, T., Katayama, Y., Hayashinaka, E., Wada, Y., Kusuhara, H., Sugiyama, Y., et al. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.10.041 · Cited by 40
Rais, R., Fletcher, S., & Polli, J. E. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22332 · Cited by 39
Dai, X., Wu, C. H., He, Y., Gui, L., Zhou, L., Guo, H., Yuan, J., Yang, B., Li, J., Deng, Q., et al. (2013) · Genetic Epidemiology · doi:10.1002/gepi.21711 · Cited by 39
Inside Out: Targeting NHE1 as an Intracellular and Extracellular Regulator of Cancer Progression
Provost, J. J., & Wallert, M. A. (2012) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12035 · Cited by 38
Lundåsen, T., Andersson, E.-M., Snaith, M., Lindmark, H., Lundberg, J., Östlund-Lindqvist, A.-M., Angelin, B., & Rudling, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037787 · Cited by 38
Chue, P. S. (2012) · Current Pharmaceutical Design · doi:10.2174/138161213804805766 · Cited by 38
Trotier-Faurion, A., Dézard, S., Taran, F., Valayannopoulos, V., de Lonlay, P., & Mabondzo, A. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400545n · Cited by 36
Bitopertin: The Good News and Bad News
GOFF, D. C. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2014.257 · Cited by 36
Takebayashi, R., Izuishi, K., Yamamoto, Y., Kameyama, R., Mori, H., Masaki, T., & Suzuki, Y. (2013) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-32-34 · Cited by 36
Using Positron Emission Tomography to Study Transporter-Mediated Drug–Drug Interactions in Tissues
Wulkersdorfer, B., Wanek, T., Bauer, M., Zeitlinger, M. A., Müller, M., & Langer, O. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.70 · Cited by 34
Riluzole increases glutamate uptake by cultured C6 astroglial cells
Dall'Igna, O. P. P., Bobermin, L. D., Souza, D. O., & Quincozes‐Santos, A. (2013) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2013.06.002 · Cited by 34
Huynh, T. H. V., Shim, I., Bohr, H. G., Abrahamsen, B., Nielsen, B., Jensen, A. A., & Bunch, L. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300345z · Cited by 33
Yoshikawa, S., Oguchi, T., Funahashi, Y., de Groat, W. C., & Yoshimura, N. (2012) · European Urology · doi:10.1016/j.eururo.2012.01.044 · Cited by 32
MacDougall, I. J. A., & Griffith, R. (2007) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2007.10.003 · Cited by 31
SERT and NET occupancy by venlafaxine and milnacipran in nonhuman primates: a PET study
Takano, A., Halldin, C., & Farde, L. (2012) · Psychopharmacology · doi:10.1007/s00213-012-2901-z · Cited by 29
Yatomi, Y., Tanaka, R., Shimura, H., Miyamoto, N., Yamashiro, K., Takanashi, M., Urabe, T., & Hattori, N. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.04.018 · Cited by 29
Yiu, W. H., Pan, C., Mead, P., Starost, M. F., Mansfield, B. C., & CHOU, J. Y. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2008.11.026 · Cited by 28
Manzardo, A. M., He, J., Poje, A. B., Penick, E. C., Campbell, J. L., & Butler, M. G. (2013) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2013.07.035 · Cited by 27
Sakamoto, S. X., Kusuhara, H., Miyata, K., Shimaoka, H., Kanazu, T., Matsuo, Y., Nomura, K., Okamura, N., Hara, S., Horie, K., et al. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.116426 · Cited by 24
The role of [¹⁸F]fluorodeoxyglucose positron emission tomography in thymic epithelial tumors.
Kaira, K., Sunaga, N., Ishizuka, T., Shimizu, K., & Yamamoto, N. (2011) · PubMed Central · doi:10.1102/1470-7330.2011.0028 · Cited by 23
New Clinical Perspectives of Hypolipidemic Drug Therapy in Severe Hypercholesterolemia
Stefanutti, C., Morozzi, C., & Giacomo, S. D. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712803341485 · Cited by 23
Sakamoto, S. X., Kusuhara, H., Horie, K., Takahashi, K., Baba, T., Ishizaki, J., & Sugiyama, Y. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.020511 · Cited by 23
Seitz, S. A., Keller, J., Schilling, A. F., Jeschke, A., Marshall, R. P., Stride, B. D., Wintermantel, T. M., Beil, F. T., Amling, M., Schütz, G., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050301 · Cited by 22
Comley, R. A., Salinas, C. A., Slifstein, M., Petrone, M., Marzano, C., Bennacef, I., Shotbolt, P., van der Aart, J., Neve, M., Iavarone, L., et al. (2013) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.202895 · Cited by 22
Guan, Z., Xu, B., Wang, R., Sun, L., & Tian, J. (2013) · PubMed · doi:10.1967/s002449910084 · Cited by 21
Research works printed but not linked: 1
- Feld, L. G. Renal glycosuria. Dayton Children's [online], (2003).
Cited by
A blood–brain barrier overview on structure, function, impairment, and biomarkers of integrity
Kadry, H., Noorani, B., & Cucullo, L. (2020) · Fluids and Barriers of the CNS · doi:10.1186/s12987-020-00230-3 · Cited by 1,853
“This includes more than 300 transporter genes encoding membrane-bound proteins that facilitate the transport of a wide array of substrates across biological membranes [130].”
BackgroundEstablishment and Dysfunction of the Blood-Brain Barrier
Zhao, Z., Nelson, A. R., Betsholtz, C., & Zlokovic, B. V. (2015) · Cell · doi:10.1016/j.cell.2015.10.067 · Cited by 1,670
A Call for Systematic Research on Solute Carriers
César-Razquin, A., Snijder, B., Frappier-Brinton, T., Isserlin, R., Gyimesi, G., Bai, X., Reithmeier, R. A., Hepworth, D., Hediger, M. A., Edwards, A. M., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.022 · Cited by 580
Understanding Cell Penetration of Cyclic Peptides
Dougherty, P. G., Sahni, A., & Pei, D. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00008 · Cited by 570
The Deubiquitylase OTUB1 Mediates Ferroptosis via Stabilization of SLC7A11
Liu, T., Jiang, L., Tavana, O., & Gu, W. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3037 · Cited by 490
Metadata
- Authors
- Lin, L., Yee, S. W., Kim, R. B., & Giacomini, K. M.
- Affiliations
- University of California, San Francisco (US)
- Western University (CA)
- Corresponding author
- Giacomini, Kathleen M.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2015-06-26
- Volume
- 14
- Issue
- 8
- Pages
- 543-560
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2191975304
- Cited by
- 835
- References
- 213
- Citations by year
- 2026: 67 · 2025: 86 · 2024: 97 · 2023: 102 · 2022: 104 · 2021: 100 · 2020: 72 · 2019: 66 · 2018: 52 · 2017: 47 · 2016: 36 · 2015: 5
- FWCI
- 5.02
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Scholarship@Western (Western University) (submittedVersion)
- Funders
- Canadian Institutes of Health Research (117588_1, MOP-89753)
- National Institute of General Medical Sciences (GM61390, U19GM061390, T32GM007175, U01GM061390)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK103729, DK103729, P30DK026743)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
- Keywords
- solute carrier transporters, therapeutic target, transporter modulation, neurotransmitter transporters, monogenic disorders, rare diseases, drug absorption, xenobiotic transport, therapeutic drugs, drug repurposing
- MeSH terms
- Animals, Biological Transport, Humans, Drug Design, Xenobiotics, Drugs, Investigational, Membrane Transport Proteins, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.